drugset / Trial / NCT03639324
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL
Non-randomizedSequentialOpen-labelTreatment
Summary
To determine the recommended phase 2 dose (RP2D) of idelalisib and venetoclax in combination with rituximab in patients with relapsed or refractory Chronic lymphocytic leukemia/ Small lymphocytic lymphoma (CLL/SLL) following a lead-in period with idelalisib and rituximab
Timeline
- Start
- 2020-10-02
- Primary completion
- 2021-10-18
- Completion
- 2021-10-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Idelalisib | Small molecule | 100 mg | — |
| Subject | Idelalisib | Small molecule | 150 mg | — |
| Subject | Venetoclax | Small molecule | 100 mg | — |
| Subject | Venetoclax | Small molecule | 200 mg | — |